Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company developing treatments for neurodegenerative and metabolic disorders and alcohol misuse disorders, announced that Rodman & Renshaw initiated coverage of the company with a Buy rating and an $8 price target. The research report was led by Michael G. King Jr., director of research and senior biotechnology analyst at Rodman & Renshaw. Quantum BioPharma said the coverage is unpaid and that it provided no consideration or fees for the report.
According to Quantum BioPharma (NASDAQ: QNTM), the initiation of coverage by a reputable analyst firm could bring increased visibility to the company's pipeline. The company is dedicated to building a portfolio of innovative assets and biotech solutions for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders, with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum is focused on the research and development of its lead compound, Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models.
Quantum also invented UNBUZZD(TM) and spun out its OTC version to Unbuzzd Wellness Inc. (“Unbuzzd”) (formerly Celly Nutrition Corp.), led by industry veterans. Quantum retains ownership of 19.84% (as of March 31, 2026) of Unbuzzd. The agreement with Unbuzzd includes royalty payments of 7% of sales from unbuzzd(TM) until payments to Quantum total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
For investors, the Buy rating and $8 price target from Rodman & Renshaw may signal confidence in Quantum's potential. This news matters because it provides a third-party validation of the company's strategy and could attract more attention to its stock. The full press release can be viewed at https://ibn.fm/6Lqsb. The latest news and updates relating to QNTM are available in the company's newsroom.
MissionIR, a specialized communications platform focused on assisting IR firms with syndicated content, disseminated the announcement. MissionIR is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries, as well as article and editorial syndication to 5,000+ outlets, enhanced press release enhancement to ensure maximum impact, social media distribution via IBN to millions of social media followers, and a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public.
